Kala Bio, INC 8-K filings

KALA BIO reported its second quarter 2024 financial results, highlighted by a $12.5 million private placement and progress in clinical trials for its lead candidate, KPI-012.

KALA BIO has entered into a securities purchase agreement for a private placement, raising approximately $12.5 million to advance its clinical development programs.

KALA BIO held its 2024 Annual Meeting where stockholders elected directors, ratified the appointment of an accounting firm, and voted on several proposals, including amendments to preferred stock designations.

KALA BIO announced its first quarter 2024 financial results, highlighting progress in its clinical trials and providing a corporate update.

KALA BIO announced its fourth quarter and full year 2023 financial results, highlighting progress in its KPI-012 clinical trial and providing a corporate update.

Kala Bio has entered into a securities purchase agreement to raise approximately $8.6 million through a private placement of Series G Convertible Preferred Stock.

KALA Bio announces it is targeting the release of topline safety and efficacy data from its Phase 2b clinical trial for KPI-012 by the end of 2024.